BioNTech SE
(XBUL:22UA)
лв
110
0 (0%)
Market Cap: 26.37 Bil
Enterprise Value: -7.22 Bil
PE Ratio: 0
PB Ratio: 1.23
GF Score: 50/100 BioNTech SE at SVB Leerink Global Healthcare Conference (Virtual) Transcript
Feb 24, 2021 / 06:00PM GMT
Daina Michelle Graybosch
SVB Leerink LLC, Research Division - MD & Senior Research Analyst
Hello, everyone. Welcome to our post-lunch fireside chat with BioNTech. I'm really thrilled that Ugur Sahin is giving us a half an hour of this time, and we could take hours, I'm sure, with everything going on with COVID infectious disease and oncology at BioNTech.
Questions & Answers
Daina Michelle Graybosch
SVB Leerink LLC, Research Division - MD & Senior Research Analyst
So with that, I think I will jump right in. I will say, please do send me any questions. There's a place to enter it below this video, and I will try to fit them in as well in this half an hour.
So maybe starting broad, Ugur. The last year has been really transformational for mRNA vaccines. And I wonder how the year now has changed BioNTech in terms of your focus and journey and what will BioNTech be in 5 years from now?
Ugur Sahin
BioNTech SE - Co-Founder, CEO & Member of Management Board
This is a great question, Daina.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot